Evogene to Present at H.C. Wainwright 27th Annual Global Investment Conference in New York
Evogene (NASDAQ: EVGN) announced its participation in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Evogene (NASDAQ: EVGN) announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference in New York from September 8-10, 2025. CEO Ofer Haviv will present on September 10, 2025, at 1:00 PM ET, focusing on the company's strategic shift towards maximizing value from its ChemPass AI technology for small molecule discovery in pharmaceutical and agricultural applications.
The presentation will showcase the company's proprietary generative AI tech-engine capabilities. One-on-one meetings with management will be available for interested investors and companies attending the conference.
Details
News Market Reaction – EVGN
On Aug 28, the day this news came out, EVGN closed 1.30% below the previous close.
Data tracked by StockTitan Argus for the Aug 28 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REHOVOT,
Mr. Haviv's in-person presentation will highlight Evogene's new strategic focus on maximizing the value of ChemPass AI, the company's proprietary generative AI tech-engine, for the discovery and optimization of small molecules in both the pharmaceutical and agriculture industries. The presentation is scheduled for Wednesday, September 10, 2025, at 1:00 PM ET.
Mr. Haviv will also be available for one-on-one meetings. Interested investors and companies attending the conference are welcome to contact Evogene's Investor Relations team (details below) or, for H.C. Wainwright clients, schedule meetings directly through the conference's online platform.
About Evogene Ltd.
Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN) is a pioneering AI-driven discovery and development company focused on creating novel small molecules for the pharmaceutical and ag-chemical industries. At the heart of Evogene's innovation is ChemPass AI, a proprietary generative AI tech-engine purpose-built to design highly potent and unique small molecules optimized across multiple critical parameters. By leveraging its tech-engine, Evogene address key challenges in small molecule discovery and optimization – significantly increasing the probability of success while reducing time and development costs. Evogene's powerful tech-engine drives product innovation through both strategic partnerships and collaborations, as well as through its internal proprietary product pipelines.
For more information, please visit: www.evogene.com.
Contact:
ir@evogene.com
Tel: +972-8-9311901
Logo: https://mma.prnewswire.com/media/1947468/Evogene_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/evogene-to-present-at-hc-wainwright-27th-annual-global-investment-conference-in-new-york-302540962.html
SOURCE Evogene
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.